FindTrial
Sign In

Effects of IL-1 beta and its receptor antagonists in the treatment of severe infection and inflammatory storm in children

Effects of IL-1beta and its receptor antagonists in the treatment of severe infection and inflammatory storm in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044203
Enrollment
Unknown
Registered
2021-03-12
Start date
2022-01-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children with severe infection

Interventions

control group:conventional therapy
experimental group:anakinra or canakinumab

Sponsors

Children's Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Children between 0 and 18 years old; 2. Severe pneumonia and/or sepsis.Patients were included who meet the guidline for diagnosis and treatment of community-acquired pneumonia in Children (2019) issued by the National Health Commission of the people's Republic of China and/or who meet the International Guide to the 2020 campaign to Save sepsis: management of septic shock and sepsis-related organ dysfunction in children.

Exclusion criteria

Exclusion criteria: 1. Notifiable infectious diseases. 2. The researcher believes that he is not suitable to participate in other situations in this study. 3. Participants in other clinical trials in the same period.

Design outcomes

Primary

MeasureTime frame
general information;IL-1 beta;—

Secondary

MeasureTime frame
infection-related indicator;—

Countries

China

Contacts

Public ContactLu Guoping

Children's Hospital of Fudan University

13788904150@163.com+86 13788904150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026